SCHEMBL6137439

SCHEMBL6137439

C#C[C@H](CCC)O[Si](C)(C)C(C)(C)C

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6137297 1.00 CA2 (0.30) CA2
SCHEMBL6137309 0.91 CA2 (0.37) CA2
SCHEMBL1057130 0.91 CA2 (0.37) CA2
SCHEMBL6137393 0.91 CA2 (0.37) CA2
SCHEMBL9794366 0.89 CA2 (0.34) CA2
SCHEMBL1057409 0.89 CA2 (0.34) CA2
SCHEMBL6137558 0.89 CA2 (0.34) CA2
SCHEMBL9794169 0.87 CA2 (0.33) CA2
SCHEMBL9794153 0.87 CA2 (0.33) CA2
SCHEMBL9794156 0.87 CA2 (0.33) CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038259-A1 Hydroxyeicosenoic acid anaglogs TAISHO PHARMACEUTICAL CO., LTD. (JP) 2005-02-17 US disclosed
EP-1425258-A4 HYDROXYEICOSENOIC ACID ANALOGS TAISHO PHARMACEUTICAL CO LTD (JP) 2005-02-16 EP disclosed
EP-1425258-A2 HYDROXYEICOSENOIC ACID ANALOGS TAISHO PHARMACEUTICAL CO., LTD (JP) 2004-06-09 EP disclosed
WO-2003024390-A2 HYDROXYEICOSENOIC ACID ANALOGS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2003-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038259-A1 Hydroxyeicosenoic acid anaglogs HCAR1, HRH4, HCAR3 CA2 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.